BioMedNewsBreaks

WednesdayFeb 19, 2025 10:33 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 1-for-50 Reverse Stock Split

CNS Pharmaceuticals (NASDAQ: CNSP) announced a 1-for-50 reverse stock split of its common stock, set to take effect on Feb. 21, 2025. The company’s shares will continue trading on Nasdaq under the symbol “CNSP” but with a new CUSIP number: 18978H409. The reverse split aims to increase the per-share trading price and ensure compliance with Nasdaq’s minimum share price requirement. As a result, every 50 shares of common stock will be consolidated into one, with proportional adjustments made to outstanding equity awards and warrants. No fractional shares will be issued, with cash payments provided instead. The number of authorized shares…

Continue Reading

TuesdayFeb 18, 2025 12:46 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at 6th Glioblastoma Drug Development Summit

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the 6th Glioblastoma Drug Development Summit, taking place Feb. 18-20, 2025, in Boston. Chief Medical Officer Dr. Sandra Silberman will present on Feb. 20 at 10:45 a.m. ET, discussing novel formulations of anthracyclines and taxanes designed to cross the blood-brain barrier. The company’s lead candidate, Berubicin, has completed patient enrollment in a pivotal study against glioblastoma, with primary analysis data expected in the first half of 2025. CNS Pharmaceuticals is also advancing TPI 287 and plans to engage with the FDA on trial design. Berubicin has received Fast Track and Orphan Drug…

Continue Reading

FridayFeb 14, 2025 3:48 pm

BioMedNewsBreaks — Adageis Bringing AI Solutions to Identify High-Risk Patients, Address Care Gaps

Adageis is reshaping the healthcare landscape, offering solutions designed to streamline workflows and align incentives with quality care outcomes. “Central to this approach is the company’s ProActive Care Platform, a patented AI-powered system that provides actionable insights to healthcare providers. The platform equips Accountable Care Organizations (‘ACOs’), Clinically Integrated Networks (‘CINs’), and Independent Physician Associations (‘IPAs’) with the tools to deliver high-quality care while meeting the financial goals of value-based models,” reads a recent article. “At the heart of the platform lies the Patented Risk Engine (‘PRE’), an AI-driven tool that analyzes patient data to identify high-risk individuals and care gaps.…

Continue Reading

ThursdayFeb 13, 2025 1:25 pm

BioMedNewsBreaks – Astiva Health Expands Community Engagement with New Activity Center in San Jose

Astiva Health announced the grand opening of its new Activity Center in San Jose, reinforcing its commitment to community wellness. The facility will serve as a hub for local seniors, offering various health and wellness programs designed to enhance quality of life. The initiative aligns with Astiva Health’s mission to provide accessible healthcare solutions and foster social engagement among its members. To view the full press release, visit https://ibn.fm/4Wlwb About Astiva Health Astiva is a leader in culturally responsive health care solutions, committed to bridging health care gaps for diverse and underserved populations. With a focus on delivering personalized care,…

Continue Reading

ThursdayFeb 13, 2025 12:02 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Prices $10 Million Public Offering at $1.70 Per Share

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care, announced the pricing of its public offering of 5,882,353 shares at $1.70 per share, expecting to raise $10 million before deductions. The offering, underwritten by MDB Capital with Paulson Investment Company LLC participating as a selected dealer, is set to close on or about Feb. 14, 2025, subject to conditions. Proceeds will support commercial-readiness efforts, R&D, clinical and regulatory projects, and general corporate purposes. The underwriter has a 45-day option to purchase up to 882,353 additional shares to cover over-allotments. To view the full press release, visit https://ibn.fm/wzvyh About…

Continue Reading

WednesdayFeb 12, 2025 2:05 pm

BioMedNewsBreaks – RenovoRx Inc. (NASDAQ: RNXT) Announces $12.1M Underwritten Public Offering

RenovoRx (NASDAQ: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath(R), a novel, FDA-cleared delivery platform, recently announced the pricing and closing of a firm commitment, underwritten public offering of 11,523,810 shares of its common stock at a price to the public of $1.05 per share. Of the approximately $12.1 million in gross proceeds, RenovoRx intends to use the net for working capital and general corporate purposes, including continued progression of its Phase III TIGeR-PaC study and the continued development and execution of commercial sales and marketing activities for RenovoCath as a standalone device. Titan Partners…

Continue Reading

TuesdayFeb 11, 2025 3:30 pm

BioMedNewsBreaks — Titan Partners Group Launches Equity Research Platform Led by Dr. Boris Peaker

Titan Partners, a division of American Capital Partners, today announced the launch of its Equity Research Division with the appointment of Boris Peaker, Ph.D., CFA, as managing director and senior equity research analyst. Dr. Peaker brings 17 years of experience in healthcare equity research and will lead the firm's research initiatives in the healthcare sector, focusing on biotechnology. “The launch of our research platform, spearheaded by Dr. Peaker, marks an important milestone in Titan’s growth,” said Jason Sands, co-founder and partner at Titan. “Our mission has always been to build a business around fundamentally strong and scientifically compelling stories. Dr.…

Continue Reading

TuesdayFeb 11, 2025 1:30 pm

BioMedNewsBreaks — Adageis Seizing Opportunity in AI-Driven Healthcare Innovation

Adageis is positioned to capitalize as artificial intelligence (“AI”) plays a crucial role in meeting quality metrics, reducing costs and improving patient outcomes in the transition toward value-based healthcare. While the sector faces challenges — such as integrating AI tools into existing systems, ensuring data security and navigating regulatory frameworks — innovators like Adageis, a forward-thinking healthcare technology company, are stepping in to bridge the gap, offering scalable solutions that align with modern needs. “Adageis is at the forefront of AI-driven healthcare innovation. Its ProActive Care Platform provides providers, clinics and health systems with tools to enhance care delivery while addressing…

Continue Reading

MondayFeb 10, 2025 2:05 pm

BioMedNewsBreaks — NextPlat Corp (NASDAQ: NXPL) Subsidiary Global Telesat Communications Expands Partnership With EVERYWHERE Communications

NextPlat (NASDAQ: NXPL, NXPLW) announced that its subsidiary, Global Telesat Communications Ltd. (GTC), has partnered with EVERYWHERE Communications, Inc. to enhance mission-critical communications for enterprise, government, and humanitarian organizations across Europe. As EVERYWHERE’s preferred connectivity solutions provider in the UK and EU, GTC will help expand real-time global communications, situational awareness, and workforce safety solutions. The partnership will introduce advanced satellite hotspots, IoT connectivity, and integrated communications platforms to support operations in remote environments. To view the full press release, visit: https://ibn.fm/9Rzgm About NextPlat Corp NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and…

Continue Reading

MondayFeb 10, 2025 1:39 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at BIO CEO & Investor Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, will participate in the BIO CEO & Investor Conference in New York on Feb. 10-11, 2025. CEO John Climaco is scheduled to present on Feb. 10 at 1:15 p.m. ET in the Royale Room. Management will also be available for one-on-one meetings, with scheduling available through the BIO CEO attendee portal. To view the full press release, visit https://ibn.fm/alIXv About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary…

Continue Reading